Plasma pharmacokinetics of ceftolozane/tazobactam in pediatric patients with cystic fibrosis
- 18 May 2020
- journal article
- research article
- Published by Wiley in Pediatric Pulmonology
- Vol. 55 (8), 2025-2032
- https://doi.org/10.1002/ppul.24815
Abstract
Background The antipseudomonal cephalosporin/β‐lactamase inhibitor combination ceftolozane/tazobactam could be a potential treatment option for cystic fibrosis (CF) pulmonary exacerbations. The pharmacokinetics (PK) of ceftolozane/tazobactam in children with CF merits further evaluation. Methods This is a retrospective subgroup analysis of a phase 1, noncomparative trial that characterized PK, safety, and tolerability of single intravenous doses of ceftolozane/tazobactam in pediatric patients. This analysis compares ceftolozane and tazobactam plasma PK parameters, estimated from a population PK model, between patients with and without CF enrolled in that trial. Individual attainment of PK/pharmacodynamic (PD) targets of ceftolozane and tazobactam (free ceftolozane concentration >4 µg/mL for >30% and free tazobactam concentration >1 µg/mL for 20% of the dosing interval) in patients with and without CF were evaluated. Results The study enrolled 18 patients aged greater than or equal to 2 to less than 18 years old, which included 9 with CF. Weight‐normalized ceftolozane PK parameters were similar between patients with CF (clearance: 0.16 L/h/kg, half‐life: 1.54 hours, volume of distribution: 0.26 L/kg) and without CF (clearance: 0.15 L/h/kg, half‐life: 1.62 hours, volume of distribution: 0.26 L/kg), as were most weight‐normalized tazobactam PK parameters. Weight‐normalized tazobactam clearance was higher in patients with CF (0.73 L/h/kg) than patients without CF (0.42 L/h/kg). All patients achieved the prespecified PK/PD targets for ceftolozane and tazobactam. Conclusions This retrospective analysis demonstrated generally similar weight‐normalized plasma PK parameters for ceftolozane and tazobactam among children with and without CF; thus, projected doses for treatment of pediatric hospital‐acquired/ventilator‐associated pneumonia, which are higher than the pediatric complicated urinary tract infection/intra‐abdominal infection doses, may be appropriate for treatment of CF pulmonary exacerbation.Keywords
Funding Information
- Merck
This publication has 10 references indexed in Scilit:
- Ceftolozane-tazobactam versus meropenem for treatment of nosocomial pneumonia (ASPECT-NP): a randomised, controlled, double-blind, phase 3, non-inferiority trialThe Lancet Infectious Diseases, 2019
- Ceftolozane-Tazobactam Population Pharmacokinetics and Dose Selection for Further Clinical Evaluation in Pediatric Patients with Complicated Urinary Tract or Complicated Intra-abdominal InfectionsAntimicrobial Agents and Chemotherapy, 2019
- Antimicrobial activity of ceftolozane–tazobactam tested against gram-negative contemporary (2015–2017) isolates from hospitalized patients with pneumonia in US medical centersDiagnostic Microbiology and Infectious Disease, 2018
- Pharmacokinetics and Safety of Single Intravenous Doses of Ceftolozane/Tazobactam in Children With Proven or Suspected Gram-Negative InfectionThe Pediatric Infectious Disease Journal, 2018
- Pharmacokinetics of single‐dose ceftaroline fosamil in children with cystic fibrosisPediatric Pulmonology, 2017
- Pharmacodynamics of Ceftolozane Combined with Tazobactam against Enterobacteriaceae in a Neutropenic Mouse Thigh ModelAntimicrobial Agents and Chemotherapy, 2016
- Population Pharmacokinetics and Safety of Ceftolozane-Tazobactam in Adult Cystic Fibrosis Patients Admitted with Acute Pulmonary ExacerbationAntimicrobial Agents and Chemotherapy, 2016
- Ceftazidime/Avibactam and Ceftolozane/Tazobactam: Second-generation β-Lactam/β-Lactamase Inhibitor CombinationsClinical Infectious Diseases, 2016
- Ceftolozane/tazobactam pharmacokinetic/pharmacodynamic‐derived dose justification for phase 3 studies in patients with nosocomial pneumoniaThe Journal of Clinical Pharmacology, 2015
- In Vivo Activities of Ceftolozane, a New Cephalosporin, with and without Tazobactam against Pseudomonas aeruginosa and Enterobacteriaceae, Including Strains with Extended-Spectrum β-Lactamases, in the Thighs of Neutropenic MiceAntimicrobial Agents and Chemotherapy, 2013